Expert Interview
A Third Look: An updated discussion of Axsome's AXS-12 (reboxetine) a selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy and cataplexy after the release of its phase 3 data.
Ticker(s): AXSMInstitution: MedStar Georgetown University Hospital
- Professor and Director of the Comprehensive Epilepsy Center in the Department of Neurology at MedStar Georgetown University Hospital.
- Currently manages more than 100 patients with obstructive sleep apnea.
- Has published numerous original research studies, reviews and has contributed several book chapters to works in the fields of epilepsy and sleep disorders.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
